Author / Suhas Gondi
-
![]()
The Risks of the Public Option
In early July, the health policy community heard a familiar proposal from familiar voices. After some restraint, Democratic presidential nominee Hillary Clinton promoted a public option insurance plan in every state as a key pillar of her health care platform, a provision that appeals to Senator Bernie Sander’s progressive base as a step toward a…
-
![]()
Big Changes in Medicare
According to a group of Congressional representatives, Medicare is due for a big change. A Democratic proposal was recently put forward that would allow the federal government to negotiate prescription drug prices for Medicare Part D. The agenda aligns with both the previous efforts of the Obama administration and plans put forward by the Clinton…
-
![]()
The 5555 Percent Drug Price Hike: Who’s to Blame?
In August 2015, Turing Pharmaceuticals acquired the rights to Daraprim, a decades-old, lifesaving drug used to cure a rare parasitic infection. Shortly after this acquisition, CEO Martin Shkreli announced that the drug would retail for $750 per tablet, a 5555 percent increase over the previous price of $13.50. For weeks, this story dominated the headlines…
-
![]()
Incentives for Quality Clinical Care
There is very little that people agree on in healthcare reform. If you’ve paid any attention to the controversy surrounding the Affordable Care Act (ACA, also known as Obamacare), you know that the policies governing our healthcare system are not only hopelessly complex, but also very contentious. Disagreements stem from fundamental ideological gaps, different theories…
